General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Amgen Inc.(SIGNIFICANT), Regeneron(SIGNIFICANT), Madrigal(SIGNIFICANT), Ionis Pharmaceuticals(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT), Beren Therapeutics(SIGNIFICANT) SPEAKER'S BUREAU: Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT), Amgen Inc.(SIGNIFICANT), Eli Lilly and Company(SIGNIFICANT), Esperion(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Novartis Corporation(SIGNIFICANT), Amgen Inc.(SIGNIFICANT), Regeneron(SIGNIFICANT), Axcella(SIGNIFICANT), Esperion(SIGNIFICANT), Altimmune(SIGNIFICANT)

View Full Disclosure